September 12, 2013

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

None of the IHC4 markers provided statistically significant prognostic information in years 5 to 10, except for nodal status and tumor size. ROR gave the strongest prognostic information in years 5 to 10. These results may help select patients who could benefit most from hormonal therapy beyond 5 years of treatment.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Šestak et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d7af6eb1cb92dd1bb8bb28 — DOI: https://doi.org/10.1093/jnci/djt244

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy· 2013 · 635 citations
Tamoxifen for early breast cancer: an overview of the randomised trials· 1998 · 4,105 citations
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial· 2008 · 916 citations

Authors

Ivana Šestak

Mitch Dowsett

Lila Zabaglo

Journals

JNCI Journal of the National Cancer Institute

Actions

Institutions

Queen Mary University of London

Royal Marsden Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion